SPARKLE2: Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

Sponsor
National Cancer Centre, Singapore (Other)
Overall Status
Recruiting
CT.gov ID
NCT04242251
Collaborator
Ministry of Health, Singapore (Other)
240
1
2
25.7
9.3

Study Details

Study Description

Brief Summary

This is a randomized controlled trial of the 'Supportive and Palliative care Review Kit in Locations Everywhere' (SPARKLE) intervention, an outpatient-based model of early palliative care. The SPARKLE intervention comprises regular symptom monitoring using questionnaires, early identification and prompt treatment of problems identified. Proactive screening for problems facilitates earlier palliative care interventions for advanced cancer patients, whenever needs arise.

Condition or Disease Intervention/Treatment Phase
  • Other: SPARKLE Model of care
N/A

Detailed Description

This is a randomized controlled trial to compare clinical outcomes between advanced cancer patients receiving and not receiving care from the SPARKLE care model, in addition to current oncologic-led palliative care model. The hypothesis is that the SPARKLE care model results in

  1. improved quality of life of both advanced cancer patients and their caregivers, and b) reduced acute healthcare utilization and costs by these patients.

Primary Study Aim: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on quality of life of advanced cancer patients. Patients' quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Functional Assessment of Cancer Therapy - General (FACT-G).

Secondary Study Aim 1: To determine the incremental effect of SPARKLE in addition to usual oncologist-led care on caregivers' quality of life. Caregiver quality of life will be measured at baseline before randomization and 16 weeks after randomization using the Singapore Caregiver Quality of Life Scale (SCQOLS), which was validated among caregivers of advanced cancer patients in Singapore.17 The PI was part of the team, led by the applicant's mentor, that developed the SCQOLS.

Secondary Study Aim 2: To determine the effect of SPARKLE in addition to usual oncologist-led care on healthcare utilization and total healthcare costs, including the costs of delivering SPARKLE, from randomization until death. Healthcare utilization and cost data will be extracted from medical and billing data. SPARKLE costs will be captured prospectively using an Activity Based Costing Approach. The study hypothesis is that per capita healthcare costs will be lower in the SPARKLE model due to fewer admissions and shorter hospital lengths of stay when admitted.

A prospective randomized controlled trial design will be used to test the effectiveness of the SPARKLE model. The recruitment target is 240 patients with advanced cancers, defined as stage 4 solid tumors including lung, colorectal, nasopharyngeal and pancreatic cancers. Eligible participants are randomized to usual care or SPARKLE intervention group using randomized permuted blocks method generated by an independent statistician, with block size kept unknown to the clinical investigators/site personnel. A total of 240 caregivers will be recruited.

The study will take place in the National Cancer Centre of Singapore (NCCS).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
The person administering the patient reported outcome measures will be blinded to the participant's allocation to study arms.
Primary Purpose:
Supportive Care
Official Title:
Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study
Actual Study Start Date :
Feb 8, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

Management by primary oncologist. Referral to existing palliative care service initiated by primary oncologist if needed.

Experimental: SPARKLE intervention group

Regular symptom monitoring and treatment of problems identified. Referral to existing palliative care services can also be initiated by the SPARKLE nurse if identified problems require follow up.

Other: SPARKLE Model of care
Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.

Outcome Measures

Primary Outcome Measures

  1. Functional Assessment of Cancer Therapy- General [16 weeks]

    Quality of life is scored on a scale of 0 to 108, with higher scores indicating better outcomes

Secondary Outcome Measures

  1. Singapore Caregiver Quality of Life Scale [16 weeks]

    Caregiver quality of life is scored on a scale of 0 to 100, with higher scores indicating better outcomes

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Patient participants Inclusion Criteria:
  • Adult aged 21 and above

  • Stage 4 solid tumor

Patient participants Exclusion Criteria:
  • Unable to complete patient-reported outcome measures

  • Already under the care of an existing palliative care service

Caregiver participants Inclusion Criteria:
  • Adult aged 21 and above
Caregiver participants Exclusion Criteria:
  • Unable to complete Singapore Caregiver Quality of Life Scale questionnaire

  • Employed caregiver to patient participants

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Cancer Centre Singapore Singapore Singapore 169610

Sponsors and Collaborators

  • National Cancer Centre, Singapore
  • Ministry of Health, Singapore

Investigators

  • Principal Investigator: Grace M Yang, MRCP, Consultant

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Cancer Centre, Singapore
ClinicalTrials.gov Identifier:
NCT04242251
Other Study ID Numbers:
  • 2019/2963
First Posted:
Jan 27, 2020
Last Update Posted:
Apr 8, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Cancer Centre, Singapore

Study Results

No Results Posted as of Apr 8, 2022